ICAD INC (ICAD) Stock Price & Overview

NASDAQ:ICADUS44934S2068

Current stock price

3.87 USD
+0.14 (+3.75%)
At close:
3.87 USD
0 (0%)
After Hours:

The current stock price of ICAD is 3.87 USD. Today ICAD is up by 3.75%. In the past month the price increased by 1.04%. In the past year, price increased by 197.69%.

ICAD Key Statistics

52-Week Range1.19 - 4.015
Current ICAD stock price positioned within its 52-week range.
1-Month Range3.58 - 3.99
Current ICAD stock price positioned within its 1-month range.
Market Cap
106.309M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.18
Dividend Yield
N/A

ICAD Stock Performance

Today
+3.75%
1 Week
-0.51%
1 Month
+1.04%
3 Months
+20.19%
Longer-term
6 Months +96.95%
1 Year +197.69%
2 Years +39.71%
3 Years +3.75%
5 Years -58.03%
10 Years +13.16%

ICAD Stock Chart

ICAD INC / ICAD Daily stock chart

ICAD Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ICAD. When comparing the yearly performance of all stocks, ICAD is one of the better performing stocks in the market, outperforming 97.09% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ICAD Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ICAD. ICAD has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ICAD Earnings

On May 13, 2025 ICAD reported an EPS of -0.02 and a revenue of 4.87M. The company beat EPS expectations (68.63% surprise) and beat revenue expectations (5.52% surprise).

Next Earnings DateAug 11, 2025
Last Earnings DateMay 13, 2025
PeriodQ1 / 2025
EPS Reported-$0.02
Revenue Reported4.874M
EPS Surprise 68.63%
Revenue Surprise 5.52%

ICAD Forecast & Estimates

10 analysts have analysed ICAD and the average price target is 3.57 USD. This implies a price decrease of -7.75% is expected in the next year compared to the current price of 3.87.

For the next year, analysts expect an EPS growth of 12.57% and a revenue growth 4.66% for ICAD


Analysts
Analysts76
Price Target3.57 (-7.75%)
EPS Next Y12.57%
Revenue Next Year4.66%

ICAD Groups

Sector & Classification

Index Membership

ICAD Financial Highlights

Over the last trailing twelve months ICAD reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -50% compared to the year before.


Income Statements
Revenue(TTM)19.53M
Net Income(TTM)-5.23M
Industry RankSector Rank
PM (TTM) N/A
ROA -13.24%
ROE -16.98%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%-1.61%
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)18.39%

ICAD Ownership

Ownership
Inst Owners31.88%
Shares27.47M
Float25.96M
Ins Owners5.51%
Short Float %N/A
Short RatioN/A

About ICAD

Company Profile

ICAD logo image iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 66 full-time employees. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.

Company Info

IPO: 1984-12-13

ICAD INC

98 Spit Brook Rd Ste 100

Nashua NEW HAMPSHIRE 03062 US

CEO: Michael Klein

Employees: 66

ICAD Company Website

ICAD Investor Relations

Phone: 16038825200

ICAD INC / ICAD FAQ

What does ICAD INC do?

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 66 full-time employees. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.


What is the stock price of ICAD INC today?

The current stock price of ICAD is 3.87 USD. The price increased by 3.75% in the last trading session.


Does ICAD INC pay dividends?

ICAD does not pay a dividend.


What is the ChartMill rating of ICAD INC stock?

ICAD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What do analysts say about ICAD INC (ICAD) stock?

10 analysts have analysed ICAD and the average price target is 3.57 USD. This implies a price decrease of -7.75% is expected in the next year compared to the current price of 3.87.


How many employees does ICAD INC have?

ICAD INC (ICAD) currently has 66 employees.